Moreover, our results from Sgk3-KO mice showed protection against glucocorticoid-induced obesity while retaining sensitivity to glucocorticoids’ immune suppression effects, highlighting SGK3 as a potential therapeutic target for addressing the metabolic side effects of glucocorticoids. This evidence concerns the gene SGK3 and obesity due to melanocortin 4 receptor deficiency.